Pirenzepine - AC Immune

Drug Profile

Pirenzepine - AC Immune

Alternative Names: ACI-91; PSY-130; PSY-130/131; PSY-131

Latest Information Update: 15 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProteoSys
  • Developer AC Immune
  • Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 31 Jan 2013 Discontinued - Phase-II for Alzheimer's disease in Germany and Austria (PO)
  • 13 Jun 2011 ACI 91 is still in phase II trials for Alzheimer's disease
  • 31 Dec 2008 Phase-II clinical trials in Alzheimer's disease in Germany and Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top